Emilia Bramanti

This study uses longitudinal in vivo imaging to show how different EGFR mutations affect resistance evolution in lung cancer lesions under therapy.

This study identifies BMI1 as a driver of Osimertinib resistance in NSCLC by promoting mitotic instability and aggressiveness, and shows that targeting BMI1 with Unesbulin can suppress tumor growth.

This study identifies a metabolic adaptation in osimertinib-resistant NSCLC cells involving acetate production via a PAA shunt, which supports redox balance and bioenergetics.

This study identifies metabolic reprogramming in osimertinib-resistant EGFR-mutant NSCLC, highlighting the pyruvate-acetaldehyde-acetate pathway and mitochondromic alterations as key drivers of resistance.